Filtered By:
Condition: Polymyositis
This page shows you your search results in order of date. This is page number 8.
Order by Relevance | Date
Total 420 results found since Jan 2013.
The prevalence and clinical characteristics of anti-HMGCR (anti-3-hydroxy-3-methyl-glutaryl-coenzyme A reductase) antibodies in idiopathic inflammatory myopathy: an analysis from the MyoCite registry
This study aimed to determine the prevalence and clinical characteristics of anti-HMGCR antibodies in idiopathic inflammatory myositis (IIM) at a tertiary care centre in northern India. Data (adult and children) were retrieved from the MyoCite dataset, identifying patients with polymyositis, dermatomyositis, and antibody-negative IIM whilst fulfilling the ACR/EULAR criteria. SLE, sarcoidosis, and systemic sclerosis were included for comparison as disease controls. The baseline clinical profile, laboratory tests, and muscle biopsies were retrieved and analysed. Descriptive statistics and non-parametric statistics were used ...
Source: Rheumatology International - January 15, 2022 Category: Rheumatology Source Type: research
Serum Myostatin and Follistatin Levels in Patients With Dermatomyositis and Polymyositis
Conclusions
Serum levels of myostatin and follistatin did not differ between dermatomyositis and PM patients and control subjects. The assessment of serum levels of myostatin and follistatin in idiopathic inflammatory myopathy patients seems not to be helpful in clinical practice.
Source: JCR: Journal of Clinical Rheumatology - December 31, 2021 Category: Rheumatology Tags: Original Articles Source Type: research
Acute respiratory distress syndrome relapsing in 10 months with an initial manifestation of polymyositis
We report a case of a patient with steroid-responsive ARDS that relapsed in 10 months with an initial manifestation of seronegative polymyositis. ARDS associated with polymyositis may develop earlier than myopathy and may relapse later.
Source: Clinical Case Reports - December 6, 2021 Category: General Medicine Authors: Yukihisa Takeda,
Mariko Ono,
Hayato Kinoshita,
Yoko Nagatomo,
Hiroki Miyauchi,
Hiroshi Tsukamoto,
Hiroyuki Nakamura,
Kazutetsu Aoshiba Tags: CASE REPORT Source Type: research
What Is in the Myopathy Literature?
This edition concentrates on inflammatory myopathies with reports of reclassification of polymyositis, cancer associations, evaluation of subclinical cardiac involvement, myositis-specific and -associated antibodies, and immune checkpoint inhibitor myositis. A number of reports address sporadic late-onset nemaline myopathy and point out its diagnostic difficulty and the importance of identifying an associated monoclonal gammopathy that is likely of clinical significance and may warrant aggressive immunotherapy. Finally, treatment of nondystrophic channelopathies is addressed.
Source: Journal of Clinical Neuromuscular Disease - November 29, 2021 Category: Neurology Tags: Review Article Source Type: research
Dipeptidyl peptidase 4/CD26 expression in human idiopathic inflammatory myopathies reveals skeletal muscle injury and vascular inflammation
CONCLUSIONS: CD26 is expressed in the IIM skeletal muscle and may represent a target of molecular intervention for patients with treatment-refractory myositis.PMID:34796850
Source: Clinical and Experimental Rheumatology - November 19, 2021 Category: Rheumatology Authors: Rebecca De Lorenzo Antonella Monno Clara Sciorati Isabella Lorenzetti Silvia Cavalli Francesco Bonomi Stefano Carlo Previtali Patrizia Rovere-Querini Source Type: research
Inflammatory myopathies: Shedding light on promising agents and combination therapies in clinical trials
Expert Opin Investig Drugs. 2021 Nov 14. doi: 10.1080/13543784.2021.2003776. Online ahead of print.ABSTRACTINTRODUCTION: Due to new insights into the pathogenesis of inflammatory myopathies -in short myositis- and the urgent need for new treatment options in patients who are refractory to standard therapy, multiple novel drugs have been developed and studied in clinical trials. In light of this exciting development, a critical evaluation of the present data is necessary in order to identify the best pathway to future treatment of inflammatory myopathies.AREAS COVERED: This review focuses on the current evidence from clinic...
Source: Expert Opinion on Investigational Drugs - November 15, 2021 Category: Drugs & Pharmacology Authors: Rachel Zeng Stefanie Glaubitz Jens Schmidt Source Type: research
